Business
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD ...
About this update from Silo Wellness Inc
[{"type":"text","content":"Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents\nLaunch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents.  “We expect that Silo’s diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy,” said Eric Weisblum, Chief Executive Officer. “AI agents are increasingly considered a fundamental part of AI infrastructure, and with Qwikagents.ai, we anticipate building a new revenue stream and driving value for our stakeholders.” According to marketsandmarkets.com, the multi-billion AI agent market is projected to reach $47–$53 billion by 2030—roughly 6x growth in 4 years. Multiple independent research firms (Markets and Markets, Grand View Research, BCC Research, Capgemini) collectively project annual growth of 43% to 50%. Qwikagents.ai has been designed to provide businesses and individuals with dedicated AI agents capable of executing tasks such as research, content generation, scheduling, and workflow automation. The platform features proprietary smart-routing technology that is expected to optimize cost and performance across multiple AI models, positioning it as a scalable solution in the rapidly growing AI agent market. “We have recently formed a subsidiary for our new business line that will operate the Qwikagents asset and future AI infrastructure technologies or businesses that we may develop or acquire,” Weisblum added. “At the same time, we remain fully committed to advancing our PTSD program into Phase 1 clinical trials. We are working to submit SPC-15’s investigational new drug application (IND) to the FD...